F S&P 500
5,074.00 -33.50 (-0.66%) F Dow Jones
38,599.00 -81.00 (-0.21%) F Nasdaq
17,459.50 -205.00 (-1.16%) E-mini Russell 2000 Index Futur
2,009.20 +2.40 (+0.12%) Petróleo
82.84 +0.03 (+0.04%) Oro
2,323.00 -15.40 (-0.66%)
Mind Medicine (MindMed) Inc. (MMED.NE)
Mind Medicine (MindMed) Inc.
One World Trade Center
Suite 8500
New York, NY 10007
United States
212-220-6633
https://www.mindmed.co
Sector(es):
Industria:
Empleados a tiempo completo: 57
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Robert Barrow | CEO & Director | 1.31M | N/D | 1989 |
| Mr. Schond L. Greenway M.B.A. | Chief Financial Officer | 469k | N/D | 1972 |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer | 906.67k | N/D | 1981 |
| Dr. Miriam Halperin Wernli Ph.D. | Executive President | 754.79k | N/D | 1953 |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor | 430k | N/D | 1957 |
| Mr. Leonard Latchman | Co-founder | N/D | N/D | N/D |
| Ms. Carrie F. Liao CPA, CGMA | VP & Chief Accounting Officer | N/D | N/D | N/D |
| Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary | N/D | N/D | 1971 |
| Dr. Francois P. Lilienthal M.B.A., M.D. | Chief Commercial Officer | N/D | N/D | N/D |
Descripción
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Mind Medicine (MindMed) Inc. a partir del 1 de abril de 2024 es 6. Las puntuaciones principales son Auditoría: 7; Junta: 5; Derechos del accionista: 3; Compensación: 8.
